Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

ZBP-89 and hypoxia-inducible factor 1a in hepatocellular carcinoma

Annual Congress on Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA

George G Chen

The Chinese University of Hong Kong, China

Keynote : J Med Oncl Ther

Abstract:

The level of hypoxia-inducible factor 1a (HIF-1a) plays an important role not only in the development of in hepatocellular carcinoma (HCC), but also in its metastasis, recurrence and resistance to anti-tumor chemotherapy. ZBP89 is a transcription factor that binds to gene promoter GCrich sequence to activate or suppress the transcription of genes that are associated with cell growth and cell death. However, the relationship between HIF-1a and ZBP-89 is unknown in HCC. In this study, we examined the levels of HIF-1a and ZBP-89 in HCC cells and HCC tissue samples. We found that the expression of HIF-1a was significantly in all HCC tumor samples, compared with non-tumor liver tissues. The levels of ZBP-89 was slightly increased in the welldifferential HCC tumor samples but obviously decreased in moderately or poorly differential tumor samples, compared with non-tumor liver tissue samples. Overall, the expression of ZBP-89 was inversely correlated with the stage of the tumor differentiation and the level of HIF-1a in HCC samples, indicating that the higher HIF-1a, the lower ZBP-89. In conclusion, there is a negative relationship between the level of HIF-1a and the expression of ZBP-89 in HCC. The data suggest that the low level of ZBP-89 may contribute to the upregulation of HIF-1a. Considering the fact that ZBP-89 can induce apoptosis in HCC cells, whether upregulation of ZBP89 will negatively impact the expression of HIF-1a remains an interesting question.

Biography:

George G Chen is a Professor in the Department of Surgery, Director of Surgical Research Laboratories and Faculty of Medicine of Chinese University of Hong Kong, China. He has extensive experience in cancer research, particularly in the area of liver and lung cancers. He has authored or co-authored more than 200 papers and has written a number of books or book chapters.
 

PDF HTML
Get the App